Chicago, IL14 Active Studies

Geographic Atrophy Clinical Trials in Chicago, IL

Find 14 actively recruiting geographic atrophy clinical trials in Chicago, IL. Connect with local research sites and explore new treatment options.

14
Active Trials
11
Sponsors
5,179
Enrolling

Recruiting Geographic Atrophy Studies in Chicago

RecruitingChicago, ILNCT04373564

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the orga...

2,076 participants
Guerbet
View Study Details
RecruitingChicago, ILNCT04368559

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen....

600 participants
Mundipharma Research Limited
View Study Details
RecruitingChicago, ILNCT06532006

A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

This is a double-blind, randomized, multiregion, comparative phase â…¢ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line...

550 participants
Shanghai Henlius Biotech
View Study Details
RecruitingChicago, ILNCT06356311

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The...

450 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingChicago, ILNCT07043400

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line the...

351 participants
BeiGene
View Study Details
RecruitingChicago, ILNCT06679855

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the ...

316 participants
NICHD Neonatal Research Network
View Study Details
RecruitingChicago, ILNCT05947071

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV). Rec...

312 participants
National Institute of Allergy and Infectious Diseases (NIAID)
View Study Details
RecruitingChicago, ILNCT05271409

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the doubl...

152 participants
Hoffmann-La Roche
View Study Details
RecruitingChicago, ILNCT06596694

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the bod...

130 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingChicago, ILNCT04468061

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts ...

110 participants
Dana-Farber Cancer Institute
View Study Details
RecruitingChicago, ILNCT04665037

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants \<2 years of age with ...

40 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingChicago, ILNCT04434040

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulatin...

40 participants
Dana-Farber Cancer Institute
View Study Details
RecruitingChicago, ILNCT03090165

Ribociclib and Bicalutamide in AR+ TNBC

This is an open label, multi-institutional, single arm phase II trial of ribociclib in combination with bicalutamide in advanced AR+ triple-negative breast cancer. No randomization or blinding is invo...

37 participants
Kari Wisinski
View Study Details
RecruitingChicago, ILNCT05487599

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

Study J3Z-MC-OJAE is a Phase 1/2, multicenter, open-label, dose-finding study of LY3884961 evaluating the safety and tolerability in adults with peripheral manifestations of GD. Up to 3 dose levels o...

15 participants
Prevail Therapeutics
View Study Details

About Geographic Atrophy Clinical Trials in Chicago

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 14 geographic atrophy clinical trials recruiting participants in Chicago, IL. These studies are seeking a combined 5,179 participants. Research is being sponsored by Guerbet, Mundipharma Research Limited, Shanghai Henlius Biotech and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in Chicago — FAQ

Are there geographic atrophy clinical trials in Chicago?

Yes, there are 14 geographic atrophy clinical trials currently recruiting in Chicago, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 14 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated March 2, 2026 from ClinicalTrials.gov